There is insufficient evidence to support the use of cinnamon for type 1 or type 2 diabetes mellitus. Further trials, which address the
issues of allocation concealment and blinding, are now required. The inclusion of other important endpoints, such as health-related
quality of life, diabetes complications and costs, is also needed.